Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 50090-7365

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 50090-7365). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
A line graph showing the mean change from baseline in ADAS-cog scores over 30 weeks of drug treatment for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis represents weeks of treatment, and the y-axis represents the change from baseline, with annotations for clinical improvement, baseline, and clinical decline. The placebo group shows a decline, while both Donepezil Hydrochloride groups show improvement or stabilization.*
FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
A cumulative percentage graph displaying patient response comparing Donepezil Hydrochloride 10 mg/day to placebo. The x-axis represents the ADCS-ADL change from baseline, while the y-axis shows the cumulative percentage of patients, illustrating differences in outcomes between the two groups.*
FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
A line graph showing SIB (Severe Impairment Battery) change from baseline over 24 weeks of drug treatment for Donepezil Hydrochloride at 10 mg/day and 23 mg/day doses. The vertical axis measures SIB change, with indicators for clinical improvement and decline, and the horizontal axis shows treatment duration in weeks. Two lines with error bars depict the mean changes for each dose over time.*
FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
A cumulative percentage curve graph displaying the change in Severe Impairment Battery (SIB) scores from baseline for patients treated with Donepezil Hydrochloride at 10 mg/day and 23 mg/day dosages. The x-axis represents SIB change from baseline, ranging from -60 to 50, and the y-axis shows the cumulative percentage of patients from 0 to 100%. Two lines compare outcomes between the two dosage groups.*
FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
A bar chart comparing percentages of patients by CIBIC-plus rating categories for Donepezil Hydrochloride 23 mg/day and 10 mg/day. The x-axis shows seven categories from 'Markedly Improved' to 'Markedly Worse' and the y-axis shows the percentage of patients. Bars indicate patient distribution across these categories for each dosage.*
FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
A cumulative percentage of patients versus change from baseline graph showing the effect of Donepezil Hydrochloride at 5 mg and 10 mg doses compared to placebo on ADAS-cog scores. The chart includes lines representing placebo, 5 mg/day, and 10 mg/day groups, with a table summarizing the percentage of patients in each treatment group who experienced various levels of change in ADAS-cog scores.*
FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
Bar chart comparing the percentage of patients with Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo across different Clinical Interview-Based Impression of Change plus caregiver input (CIBIC-plus) ratings, ranging from Markedly Improved to Markedly Worse.*
FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
Line graph showing ADAS-cog change from baseline over weeks of drug treatment for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis represents mean change with standard error, indicating clinical improvement or decline. Data points show improvement for both dosages compared to placebo, with placebo group showing decline after 12 weeks.*
FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
A cumulative percentage graph showing the change from baseline in cognitive function for patients treated with Donepezil Hydrochloride at 5 mg/day and 10 mg/day compared to placebo. The x-axis represents change from baseline with markers at -7 and -4 points indicating improvement, and the y-axis shows cumulative percentage of patients. Data highlights greater improvements in the Donepezil groups versus placebo, with tabulated percentages of patients achieving changes in ADAS-cog scores at -7, -4, and 0 points by treatment group.*
FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
A bar chart comparing the percentage of patients across different CIBIC-plus Rating categories for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. Categories range from Markedly Improved to Markedly Worse, showing distribution of patient outcomes by treatment type.*
FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
A line graph showing SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment. The graph compares Donepezil Hydrochloride 10 mg/day and placebo, with SIB change on the vertical axis and months of treatment on the horizontal axis. Donepezil shows clinical improvement, while placebo indicates clinical decline.*
FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
A cumulative percentage curve graph comparing Donepezil Hydrochloride 10 mg/day and placebo groups. The x-axis represents SIB change from baseline, ranging from 30 to approximately -75, and the y-axis shows the cumulative percentage of patients from 0% to 100%. The graph shows treatment and placebo response distributions.*
FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
A line graph displaying the mean change from baseline in ADCS-ADL scores over 0, 3, and 6 months of drug treatment. It compares Donepezil Hydrochloride 10 mg/day (solid line with circles) and placebo (dashed line with squares). The vertical axis ranges from clinical improvement to clinical decline, showing scores decreasing over time for both groups, with placebo declining more steeply.*
FDA Label Image

Chemical Structure (Donepezil Str)

Chemical Structure (Donepezil Str)
Chemical structure of Donepezil Hydrochloride showing its molecular components including aromatic rings, piperidine ring, and hydrochloride group.*
FDA Label Image

Label Image (Lbl500907365)

Label Image (Lbl500907365)
Donepezil Hydrochloride 5 mg film coated tablets label from A-S Medication Solutions. The label shows product and lot numbers, storage instructions to keep at 68 to 77 degrees Fahrenheit, and packaging details including 90 tablets. It is an oral prescription medication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.